A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
Status:
Recruiting
Trial end date:
2022-12-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166
and of branebrutinib, each versus placebo, for the treatment of participants with moderate to
severe atopic dermatitis.